MX2019006803A - Composicion farmaceutica para prevenir o tratar la hepatitis b. - Google Patents

Composicion farmaceutica para prevenir o tratar la hepatitis b.

Info

Publication number
MX2019006803A
MX2019006803A MX2019006803A MX2019006803A MX2019006803A MX 2019006803 A MX2019006803 A MX 2019006803A MX 2019006803 A MX2019006803 A MX 2019006803A MX 2019006803 A MX2019006803 A MX 2019006803A MX 2019006803 A MX2019006803 A MX 2019006803A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
quadruplex
hbv
preventing
oligonucleotide
Prior art date
Application number
MX2019006803A
Other languages
English (en)
Inventor
Hwan KIM Kyun
Hyun Kim Doo
Min Park Yeong
Original Assignee
Am Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am Sciences Inc filed Critical Am Sciences Inc
Publication of MX2019006803A publication Critical patent/MX2019006803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para tratar o prevenir hepatitis B, que comprende: al menos un oligonucleótido seleccionado del grupo que consiste en un oligonucleótido representado por una secuencia de ácidos nucleicos de SEQ ID NO: 1, 2 o 6 o una secuencia de ácidos nucleicos complementaria de la misma; y un oligonucleótido que tiene al menos una modificación química en el oligonucleótido, como principio activo y a procedimiento para cribar un agente terapéutico para hepatitis B de acuerdo con la formación de un G-quadruplex con VHB y un material candidato. La composición farmacéutica forma un G-quadruplex con VHB y reduce ADNccc (ADN circular covalentemente cerrado) y por tanto se puede utilizar en el tratamiento o prevención de hepatitis B.
MX2019006803A 2016-12-13 2017-12-13 Composicion farmaceutica para prevenir o tratar la hepatitis b. MX2019006803A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160169681 2016-12-13
PCT/KR2017/014662 WO2018110980A1 (ko) 2016-12-13 2017-12-13 B형 간염 예방 또는 치료용 의약 조성물

Publications (1)

Publication Number Publication Date
MX2019006803A true MX2019006803A (es) 2019-11-18

Family

ID=62558961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006803A MX2019006803A (es) 2016-12-13 2017-12-13 Composicion farmaceutica para prevenir o tratar la hepatitis b.

Country Status (10)

Country Link
US (1) US11033571B2 (es)
EP (1) EP3556402A4 (es)
JP (1) JP6811338B2 (es)
KR (1) KR101954130B1 (es)
CN (1) CN110392581A (es)
AU (1) AU2017375819B2 (es)
CA (1) CA3047076A1 (es)
MX (1) MX2019006803A (es)
RU (1) RU2019120163A (es)
WO (1) WO2018110980A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression
WO2019240503A1 (ko) * 2018-06-12 2019-12-19 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
EP3863662A1 (en) * 2018-10-12 2021-08-18 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
CN114829599A (zh) * 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
US20220056451A1 (en) * 2020-07-27 2022-02-24 Aligos Therapeutics, Inc. Hbv binding oligonucleotides and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
WO2000016802A1 (en) * 1998-09-21 2000-03-30 University Of Massachusetts Hepatitis b core antigen nucleic acid vaccine
CN100365009C (zh) * 2003-08-06 2008-01-30 北京三诺佳邑生物技术有限责任公司 一组抗hbv感染及防治乙型肝炎的核苷酸序列及其应用
WO2011145885A2 (ko) 2010-05-18 2011-11-24 연세대학교 산학협력단 B형 간염 치료활성 물질의 스크리닝용 조성물 및 스크리닝 방법
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
CN103403158B (zh) 2011-08-11 2015-01-28 松下电器产业株式会社 检测g-四联体螺旋形成的方法
ITMI20120275A1 (it) 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
CA2874828A1 (en) 2012-06-01 2013-12-05 Drexel University Modulation of hepatitis b virus cccdna transcription
EP2992098B1 (en) * 2013-05-01 2019-03-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating hbv and ttr expression
WO2015042711A1 (en) * 2013-09-25 2015-04-02 Engene, Inc. Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

Also Published As

Publication number Publication date
KR101954130B1 (ko) 2019-03-05
JP2020513421A (ja) 2020-05-14
US11033571B2 (en) 2021-06-15
WO2018110980A1 (ko) 2018-06-21
AU2017375819A1 (en) 2019-07-25
RU2019120163A3 (es) 2021-01-15
AU2017375819B2 (en) 2021-01-28
KR20180068320A (ko) 2018-06-21
EP3556402A4 (en) 2020-08-05
JP6811338B2 (ja) 2021-01-13
RU2019120163A (ru) 2021-01-15
CA3047076A1 (en) 2018-06-21
CN110392581A (zh) 2019-10-29
US20190343864A1 (en) 2019-11-14
EP3556402A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
MX2019006803A (es) Composicion farmaceutica para prevenir o tratar la hepatitis b.
FI3604532T3 (fi) Uusia crispr-entsyymejä ja järjestelmiä
WO2017213898A3 (en) Rna guided compositions for preventing and treating hepatitis b virus infections
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
RU2022103603A (ru) Направляемые нуклеиновыми кислотами нуклеазы
WO2020198509A3 (en) Modified oligonucleotides with increased stability
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
CY1118029T1 (el) Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus
WO2017053431A3 (en) Allele selective gene editing and uses thereof
EP4372091A3 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
WO2017019891A3 (en) Compositions and methods for silencing hepatitis b virus gene expression
NZ733882A (en) Compositions for modulating c9orf72 expression
MX2022013356A (es) Avv que codifica mirna dirigido al gen htt y usos del mismo.
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
RS53236B (en) BETA-AMYLOIDOSIS PEPTIDES
Han et al. A synthetic small molecule for targeted transcriptional activation of germ cell genes in a human somatic cell
ATE467688T1 (de) Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
MX2009008139A (es) Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos.
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
WO2017066719A3 (en) Hu specific interfering agents
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
EA201890379A1 (ru) Терапевтические олигонуклеотиды
MX2020010959A (es) Moleculas de empalme trans.
MX2020012652A (es) Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
MX2019015143A (es) Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso.